{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:25:53Z","timestamp":1783905953984,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373441"],"award-info":[{"award-number":["82373441"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203577"],"award-info":[{"award-number":["82203577"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lung adenocarcinoma (LUAD) is the major histological subtype of non-small cell lung cancer (NSCLC). The mechanistic target of rapamycin complex 1 (mTORC1), a master regulator of anabolic growth and metabolism, has been implicated in unfavorable prognosis and therapeutic resistance in LUAD. Nevertheless, how this association is mechanistically established remains insufficiently understood. Here, by integrating TCGA\/GEO datasets with our institutional LUAD single-cell RNA-seq, we identified the atypical E2F factor E2F8 as the member most closely associated with the mTORC1 pathway and found that E2F8 is upregulated in LUAD and that higher E2F8 levels correlate with adverse clinicopathological features and poorer prognosis. In PC-9 and H1975 cells, E2F8 overexpression enhanced proliferation, clonogenicity, migration, and xenograft growth, whereas E2F8 silencing produced the opposite effects; rapamycin partially reversed these phenotypes, indicating mTORC1 dependence. Mechanistically, E2F8 activated transcription of the HECT-type E3 ligase WWP1, which recognized PPxY-containing TSC1 and mediated K48-linked polyubiquitination at K662, promoting proteasomal degradation of TSC1 and sustaining mTORC1 signaling, as evidenced by increased\n                    <jats:italic>p<\/jats:italic>\n                    -mTOR (Ser2448),\n                    <jats:italic>p<\/jats:italic>\n                    -S6K1, and\n                    <jats:italic>p<\/jats:italic>\n                    -4EBP1. WWP1 knockdown markedly blunted E2F8-induced mTORC1 activation, preserved TSC1 abundance, and attenuated downstream mTORC1 readouts under E2F8\/WWP1 activation, supporting TSC1 as the critical substrate. Pharmacologic WWP1 inhibition with indole-3-carbinol (I3C) restored TSC1, reduced\n                    <jats:italic>p<\/jats:italic>\n                    -mTOR (Ser2448), and suppressed LUAD xenograft growth, defining an E2F8-WWP1-TSC1-mTORC1 axis as a targetable circuit in LUAD.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08863-2","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:30:10Z","timestamp":1779208210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["E2F-mediated activation of mTORC1 through the ubiquitin-proteasome system promotes lung adenocarcinoma progression"],"prefix":"10.1038","volume":"17","author":[{"given":"Wentao","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shina","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-6707","authenticated-orcid":false,"given":"Zizhang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-1109","authenticated-orcid":false,"given":"Ke","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5975-542X","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"8863_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8863_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24:1206\u201318.","journal-title":"Lancet Oncol"},{"key":"8863_CR3","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/S0140-6736(24)01299-6","volume":"403","author":"The Lancet.","year":"2024","unstructured":"The Lancet. Lung cancer treatment: 20 years of progress. Lancet. 2024;403:2663.","journal-title":"Lancet"},{"key":"8863_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71244","volume":"14","author":"JMJ Punnasseril","year":"2025","unstructured":"Punnasseril JMJ, Auwal A, Gopalan V, Lam AK, Islam F. Metabolic reprogramming of cancer cells and therapeutics targeting cancer metabolism. Cancer Med. 2025;14:e71244.","journal-title":"Cancer Med"},{"key":"8863_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02165-x","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y, et al. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer. 2024;23:261.","journal-title":"Mol Cancer"},{"key":"8863_CR6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41580-023-00641-8","volume":"24","author":"C Goul","year":"2023","unstructured":"Goul C, Peruzzo R, Zoncu R. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease. Nat Rev Mol Cell Biol. 2023;24:857\u201375.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8863_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274\u201393.","journal-title":"Cell"},{"key":"8863_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8:375.","journal-title":"Signal Transduct Target Ther"},{"key":"8863_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960\u201376.","journal-title":"Cell"},{"key":"8863_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01820-z","volume":"22","author":"A Marques-Ramos","year":"2023","unstructured":"Marques-Ramos A, Cervantes R. Expression of mTOR in normal and pathological conditions. Mol Cancer. 2023;22:112.","journal-title":"Mol Cancer"},{"key":"8863_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.trecan.2016.03.008","volume":"2","author":"E Ilagan","year":"2016","unstructured":"Ilagan E, Manning BD. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer. 2016;2:241\u201351.","journal-title":"Trends Cancer"},{"key":"8863_CR12","first-page":"476","volume":"4","author":"Y Dobashi","year":"2011","unstructured":"Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol. 2011;4:476\u201395.","journal-title":"Int J Clin Exp Pathol"},{"key":"8863_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/aps.2012.143","volume":"34","author":"LX Dong","year":"2013","unstructured":"Dong LX, Sun LL, Zhang X, Pan L, Lian LJ, Chen Z, et al. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells. Acta Pharmacol Sin. 2013;34:314\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"8863_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.tips.2025.03.009","volume":"46","author":"AN Gargalionis","year":"2025","unstructured":"Gargalionis AN, Papavassiliou KA, Papavassiliou AG. KRAS(G12C)\/mTORC1 inhibition: a powerful duo in NSCLC therapeutics. Trends Pharmacol Sci. 2025;46:389\u201391.","journal-title":"Trends Pharmacol Sci"},{"key":"8863_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.7150\/ijbs.99954","volume":"21","author":"Z Xu","year":"2025","unstructured":"Xu Z, Wang L, Tu L, Liu T, Zhang Y, He Y, et al. Folic acid-modified milk exosomes delivering c-Kit siRNA overcome EGFR-TKIs resistance in lung cancer by suppressing mTOR signaling and stemness. Int J Biol Sci. 2025;21:382\u201399.","journal-title":"Int J Biol Sci"},{"key":"8863_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.tcb.2009.01.002","volume":"19","author":"T Lammens","year":"2009","unstructured":"Lammens T, Li J, Leone G, De Veylder L. Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol. 2009;19:111\u20138.","journal-title":"Trends Cell Biol"},{"key":"8863_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ceb.2007.10.006","volume":"19","author":"PJ Iaquinta","year":"2007","unstructured":"Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol. 2007;19:649\u201357.","journal-title":"Curr Opin Cell Biol"},{"key":"8863_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","volume":"19","author":"LN Kent","year":"2019","unstructured":"Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19:326\u201338.","journal-title":"Nat Rev Cancer"},{"key":"8863_CR19","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1158\/0008-5472.CAN-09-3082","volume":"70","author":"Q Deng","year":"2010","unstructured":"Deng Q, Wang Q, Zong WY, Zheng DL, Wen YX, Wang KS, et al. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res. 2010;70:782\u201391.","journal-title":"Cancer Res"},{"key":"8863_CR20","doi-asserted-by":"crossref","unstructured":"Park SA, Platt J, Lee JW, L\u00f3pez-Gir\u00e1ldez F, Herbst RS, Koo JS. E2F8 as a novel therapeutic target for lung cancer. J Natl Cancer Inst. 2015;107:djv151.","DOI":"10.1093\/jnci\/djv151"},{"key":"8863_CR21","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1038\/s41388-021-01855-w","volume":"40","author":"S Wang","year":"2021","unstructured":"Wang S, Cao K, Liao Y, Zhang W, Zheng J, Li X, et al. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma. Oncogene. 2021;40:4368\u201383.","journal-title":"Oncogene"},{"key":"8863_CR22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.biopha.2017.05.118","volume":"92","author":"J Tian","year":"2017","unstructured":"Tian J, Lin Y, Yu J. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL. Biomed Pharmacother. 2017;92:919\u201326.","journal-title":"Biomed Pharmacother"},{"key":"8863_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7150\/ijbs.37686","volume":"16","author":"LK Kim","year":"2020","unstructured":"Kim LK, Park SA, Eoh KJ, Heo TH, Kim YT, Kim HJ. E2F8 regulates the proliferation and invasion through epithelial-mesenchymal transition in cervical cancer. Int J Biol Sci. 2020;16:320\u20139.","journal-title":"Int J Biol Sci"},{"key":"8863_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115854","volume":"218","author":"K Liu","year":"2023","unstructured":"Liu K, Wang L, Lou Z, Guo L, Xu Y, Qi H, et al. E2F8 exerts cancer-promoting effects by transcriptionally activating RRM2 and E2F8 knockdown synergizes with WEE1 inhibition in suppressing lung adenocarcinoma. Biochem Pharmacol. 2023;218:115854.","journal-title":"Biochem Pharmacol"},{"key":"8863_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41388-024-03239-2","volume":"44","author":"F Huang","year":"2025","unstructured":"Huang F, Li K, Chen Z, Cui Z, Hankey W, Fang K, et al. Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer. Oncogene. 2025;44:481\u201393.","journal-title":"Oncogene"},{"key":"8863_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06380-0","volume":"14","author":"A Behera","year":"2023","unstructured":"Behera A, Reddy ABM. WWP1 E3 ligase at the crossroads of health and disease. Cell Death Dis. 2023;14:853.","journal-title":"Cell Death Dis"},{"key":"8863_CR27","doi-asserted-by":"publisher","first-page":"e61027","DOI":"10.1371\/journal.pone.0061027","volume":"8","author":"B Yeung","year":"2013","unstructured":"Yeung B, Ho KC, Yang X. WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells. PLoS ONE. 2013;8:e61027.","journal-title":"PLoS ONE"},{"key":"8863_CR28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.7150\/thno.63627","volume":"12","author":"CH Tung","year":"2022","unstructured":"Tung CH, Huang MF, Liang CH, Wu YY, Wu JE, Hsu CL, et al. \u03b1-Catulin promotes cancer stemness by antagonizing WWP1-mediated KLF5 degradation in lung cancer. Theranostics. 2022;12:1173\u201386.","journal-title":"Theranostics"},{"key":"8863_CR29","doi-asserted-by":"crossref","unstructured":"Kishikawa T, Higuchi H, Wang L, Panch N, Maymi V, Best S, et al. WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. J Clin Investig. 2021;131:e140436.","DOI":"10.1172\/JCI140436"},{"key":"8863_CR30","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/leu.2017.342","volume":"32","author":"AG Sanarico","year":"2018","unstructured":"Sanarico AG, Ronchini C, Croce A, Memmi EM, Cammarata UA, De Antoni A, et al. The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. Leukemia. 2018;32:911\u20139.","journal-title":"Leukemia"},{"key":"8863_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-025-00688-x","volume":"20","author":"T Hu","year":"2025","unstructured":"Hu T, Shi R, Yin S, Xu T, Xu Y, Xu D, et al. HMGA1 promotes the progression of lung adenocarcinoma through the STAT1-mediated transcriptional activation of DDAH1. Biol Direct. 2025;20:101.","journal-title":"Biol Direct"},{"key":"8863_CR32","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/onc.2015.375","volume":"35","author":"MB Schabath","year":"2016","unstructured":"Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016;35:3209\u201316.","journal-title":"Oncogene"},{"key":"8863_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/0008-5472.CAN-11-1403","volume":"72","author":"H Okayama","year":"2012","unstructured":"Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR\/KRAS\/ALK-negative lung adenocarcinomas. Cancer Res. 2012;72:100\u201311.","journal-title":"Cancer Res"},{"key":"8863_CR34","doi-asserted-by":"publisher","first-page":"186ra66","DOI":"10.1126\/scitranslmed.3005723","volume":"5","author":"S Rousseaux","year":"2013","unstructured":"Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5:186ra66.","journal-title":"Sci Transl Med"},{"key":"8863_CR35","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2:100141.","journal-title":"Innovation"},{"key":"8863_CR36","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s00018-017-2481-5","volume":"74","author":"VC Figueiredo","year":"2017","unstructured":"Figueiredo VC, Markworth JF, Cameron-Smith D. Considerations on mTOR regulation at serine 2448: implications for muscle metabolism studies. Cell Mol Life Sci. 2017;74:2537\u201345.","journal-title":"Cell Mol Life Sci"},{"key":"8863_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ccell.2015.10.004","volume":"28","author":"S Sun","year":"2015","unstructured":"Sun S, Chen S, Liu F, Wu H, McHugh J, Bergin IL, et al. Constitutive activation of mTORC1 in endothelial cells leads to the development and progression of lymphangiosarcoma through VEGF autocrine signaling. Cancer Cell. 2015;28:758\u201372.","journal-title":"Cancer Cell"},{"key":"8863_CR38","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366:818\u201322.","journal-title":"Science"},{"key":"8863_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1006\/mcne.1998.0677","volume":"11","author":"JD Wood","year":"1998","unstructured":"Wood JD, Yuan J, Margolis RL, Colomer V, Duan K, Kushi J, et al. Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins. Mol Cell Neurosci. 1998;11:149\u201360.","journal-title":"Mol Cell Neurosci"},{"key":"8863_CR40","doi-asserted-by":"publisher","first-page":"D512","DOI":"10.1093\/nar\/gku1267","volume":"43","author":"PV Hornbeck","year":"2015","unstructured":"Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015;43:D512\u201320.","journal-title":"Nucleic Acids Res"},{"key":"8863_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0159","volume":"364","author":"YR Lee","year":"2019","unstructured":"Lee YR, Chen M, Lee JD, Zhang J, Lin SY, Fu TM, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019;364:eaau0159.","journal-title":"Science"},{"key":"8863_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21:183\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8863_CR43","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-22-0602","volume":"82","author":"KC Wood","year":"2022","unstructured":"Wood KC, Gutkind JS. Challenges and emerging opportunities for targeting mTOR in cancer. Cancer Res. 2022;82:3884\u20137.","journal-title":"Cancer Res"},{"key":"8863_CR44","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1126\/science.1157535","volume":"320","author":"Y Sancak","year":"2008","unstructured":"Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 2008;320:1496\u2013501.","journal-title":"Science"},{"key":"8863_CR45","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/ncb1753","volume":"10","author":"E Kim","year":"2008","unstructured":"Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol. 2008;10:935\u201345.","journal-title":"Nat Cell Biol"},{"key":"8863_CR46","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.cmet.2018.11.006","volume":"29","author":"R Wu","year":"2019","unstructured":"Wu R, Dang F, Li P, Wang P, Xu Q, Liu Z, et al. The Circadian Protein Period2 Suppresses mTORC1 Activity via Recruiting Tsc1 to mTORC1 Complex. Cell Metab. 2019;29:653\u201367.e6.","journal-title":"Cell Metab"},{"key":"8863_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114543","volume":"43","author":"JN Joshi","year":"2024","unstructured":"Joshi JN, Lerner AD, Scallo F, Grumet AN, Matteson P, Millonig JH, et al. mTORC1 activity oscillates throughout the cell cycle, promoting mitotic entry and differentially influencing autophagy induction. Cell Rep. 2024;43:114543.","journal-title":"Cell Rep"},{"key":"8863_CR48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molmed.2024.10.009","volume":"31","author":"J Hartung","year":"2025","unstructured":"Hartung J, Muller C, Calkhoven CF. The dual role of the TSC complex in cancer. Trends Mol Med. 2025;31:452\u201365.","journal-title":"Trends Mol Med"},{"key":"8863_CR49","doi-asserted-by":"publisher","first-page":"8313","DOI":"10.1074\/jbc.C500451200","volume":"281","author":"H Chong-Kopera","year":"2006","unstructured":"Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, Rosa JL, et al. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem. 2006;281:8313\u20136.","journal-title":"J Biol Chem"},{"key":"8863_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.616747","volume":"8","author":"W Liu","year":"2020","unstructured":"Liu W, Yi Y, Zhang C, Zhou B, Liao L, Liu W, et al. The expression of TRIM6 activates the mTORC1 pathway by regulating the ubiquitination of TSC1-TSC2 to promote renal fibrosis. Front Cell Dev Biol. 2020;8:616747.","journal-title":"Front Cell Dev Biol"},{"key":"8863_CR51","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/onc.2017.349","volume":"37","author":"P Guo","year":"2018","unstructured":"Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y, et al. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex. Oncogene. 2018;37:478\u201388.","journal-title":"Oncogene"},{"key":"8863_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41420-021-00532-x","volume":"7","author":"X Hu","year":"2021","unstructured":"Hu X, Yu J, Lin Z, Feng R, Wang ZW, Chen G. The emerging role of WWP1 in cancer development and progression. Cell Death Discov. 2021;7:163.","journal-title":"Cell Death Discov"},{"key":"8863_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108631","volume":"257","author":"SM Stribbling","year":"2024","unstructured":"Stribbling SM, Beach C, Ryan AJ. Orthotopic and metastatic tumour models in preclinical cancer research. Pharmacol Ther. 2024;257:108631.","journal-title":"Pharmacol Ther"},{"key":"8863_CR54","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41416-020-01032-y","volume":"123","author":"R Yang","year":"2020","unstructured":"Yang R, Wang M, Zhang G, Bao Y, Wu Y, Li X, et al. E2F7-EZH2 axis regulates PTEN\/AKT\/mTOR signalling and glioblastoma progression. Br J Cancer. 2020;123:1445\u201355.","journal-title":"Br J Cancer"},{"key":"8863_CR55","doi-asserted-by":"crossref","unstructured":"Xie Y, Li H, Luo X, Li H, Gao Q, Zhang L, et al. IBS 2.0: an upgraded illustrator for the visualization of biological sequences. Nucleic Acids Res. 2022;50(W1):W420\u2013w6.","DOI":"10.1093\/nar\/gkac373"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08863-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:01:18Z","timestamp":1783904478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08863-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8863"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08863-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Nanjing Medical University Institutional Animal Care and Research Committee (IACUC code: IACUC-2411035-1) and were performed in accordance with the relevant guidelines and regulations. Tissue samples were collected from patients with approval from the Ethics Committee of Jiangsu Province Hospital (Approval Number: 2024-SR-139). Prior to participation, all participants provided informed consent. All methods involving human participants were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have consented to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"635"}}